# Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars

> **NCT00620737** · PHASE2 · WITHDRAWN · sponsor: **Castle Creek Biosciences, LLC.**

## Conditions studied

- Restrictive Burn Scars of Joint Area

## Interventions

- **BIOLOGICAL:** Autologous Human Fibroblasts (Isolagen TherapyTM)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00620737
- **Lead sponsor:** Castle Creek Biosciences, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-02
- **Primary completion:** 2008-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2012-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00620737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00620737, "Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00620737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*